Clinical Trials for Stomach Cancer

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: First-line trial in adults with unresectable/metastatic, centrally confirmed HER2-positive gastric/GEJ adenocarcinoma (main cohort PD-L1 CPS ≥1; exploratory CPS <1) comparing trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor) plus a fluoropyrimidine ± pembrolizumab versus standard trastuzumab plus platinum/fluoropyrimidine chemotherapy ± pembrolizumab. Key exclusions include prior HER2 therapy, significant cardiac/pulmonary disease, and history of ILD/pneumonitis.

ClinicalTrials.gov ID: NCT06731478

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory CD19-positive B‑cell malignancies (DLBCL/high‑grade B‑cell lymphoma, transformed/Richter, B‑ALL/B‑LBL, or CML in lymphoid blast crisis) receive targeted conditioning with 131‑I apamistamab (anti‑CD45 radiolabeled mAb delivering marrow/lymphoid radiation) followed by 19‑28z CD19‑directed CAR T cells. Prior CD19 therapies (including CAR T) are allowed with confirmed CD19 expression; key exclusions include uncontrolled infection, significant cardiac disease, active GVHD/autoimmune disease requiring systemic T‑cell suppression, and inadequate organ function.

ClinicalTrials.gov ID: NCT04512716

Adaptive Radiation for Abdominopelvic Metastases (ARAM)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic solid tumors limited to abdominopelvic lesions (ECOG 0–1, no prior RT to target, ≤5 active metastases) receive adaptive stereotactic body radiation therapy with daily online plan adaptation, using dose-escalated SBRT (8–10 Gy/fx) to optimize target coverage while monitoring for grade ≥3 toxicity. Single-arm dose-escalation study; excludes peritoneal carcinomatosis and active extra-abdominopelvic disease.

ClinicalTrials.gov ID: NCT05880667

Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with symptomatic malignant gastric outlet obstruction from distal gastric or duodenal tumors, suitable for surgical bypass and general anesthesia, are randomized to laparoscopic Roux-en-Y gastric bypass versus standard loop gastrojejunostomy for palliative restoration of oral intake. The trial compares postoperative gastric emptying and diet tolerance, along with complications, reoperation, short-term survival, and quality of life.

ClinicalTrials.gov ID: NCT05986890

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic gastric/GEJ adenocarcinoma that is HER2-negative, CLDN18.2-positive, and PD-L1–positive (ECOG 0–1) are randomized to pembrolizumab plus CAPOX or mFOLFOX6 with either zolbetuximab or placebo. Zolbetuximab is a CLDN18.2-targeted IgG1 monoclonal antibody that mediates ADCC/CDC; key exclusions include prior metastatic-line therapy (beyond one initial dose), active autoimmune disease, immune pneumonitis, CNS mets, significant GI obstruction/bleeding, and >grade 1 neuropathy.

ClinicalTrials.gov ID: NCT06901531

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Newly diagnosed, unresectable/metastatic, SSTR-positive, well-differentiated G1–G2 (Ki-67 &lt;10%) advanced GEP-NETs with high disease burden (adolescents/adults, ECOG 0–1) randomized to [177Lu]Lu-DOTA-TATE plus octreotide LAR versus octreotide LAR alone. [177Lu]Lu-DOTA-TATE is a somatostatin receptor–targeted peptide receptor radionuclide therapy delivering beta-emitting 177Lu via DOTA-TATE to SSTR2-expressing tumors.

ClinicalTrials.gov ID: NCT06784752

A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HER2-positive locally advanced/metastatic solid tumors receive single-agent YH32367 (nesfrotamig/ABL105), a HER2×4‑1BB bispecific antibody that blocks HER2 signaling and provides localized 4‑1BB costimulation to T/NK cells; dose expansion focuses on previously treated HER2+ biliary tract cancer and other non–breast/gastric/GEJ HER2+ solid tumors after standard options. Key exclusions include active/unstable CNS disease, significant cardiac disease, ILD/pneumonitis, autoimmune disease requiring immunosuppression, and active viral hepatitis/HIV.

ClinicalTrials.gov ID: NCT05523947

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Eligible patients are adults with select advanced or metastatic solid tumors (including colorectal, cholangiocarcinoma, appendiceal, pancreatic, gastric, endometrial, triple negative breast, ovarian, or prostate cancers) who have exhausted standard therapies; phase 2 focuses on colorectal cancer. Therapy is with APL-5125, an oral CK2α kinase inhibitor targeting Wnt signaling.

ClinicalTrials.gov ID: NCT06399757